•
Sep 30, 2023
Kodiak Sciences Q3 2023 Earnings Report
Kodiak Sciences reported results for the quarter ended September 30, 2023, highlighting the reboot of the tarcocimab program and progress in the KSI-501 clinical program.
Key Takeaways
Kodiak Sciences reported a net loss of $50.0 million for the third quarter of 2023. The company ended the quarter with $345.7 million in cash and cash equivalents. The company is focusing on its pipeline of retinal disease prospects and plans to reboot the tarcocimab program.
Tarcocimab pivotal program: GLOW phase 3 study met its primary endpoint with a 29-fold increased response rate ratio.
KSI-501 clinical program: Phase 1 study of KSI-501 ABC has completed enrollment and dosing phases, with clinical data expected in Q1 2024.
Kodiak plans to develop both the KSI-501 ABC bioconjugate and the KSI-501 P unconjugated protein.
Kodiak ended the third quarter of 2023 with $345.7 million in cash and cash equivalents.